Even among NSCLC patients with PD-L1 expression > 50% treated with first-line pembrolizumab, clinical outcome resulted significantly improved in patients with a PD-L1 expression > 90% [29]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.